XTalks

NOVEMBER 3, 2022

Eli Lilly is finding itself in an enviable position with its newly launched diabetes injection Mounjaro (tirzepatide) and blockbuster diabetes med Trulicity due to temporary shortages of competitor Novo Nordisk’s diabetes drug Ozempic (semaglutide). In the third quarter of 2022, Mounjaro scored $187.3

Sales 98

Sales FDA Approval Production Insulin 98

Pharmaceutical Technology

JANUARY 17, 2023

Mounjaro is anticipated to launch in the US later this year or by early 2024. Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies. Bimagrumab is an activin receptor type 2B (ACVR2B or EC 2.7.11.30) antagonist that offers a unique mechanism of action within the obesity market.

Development 130

Development Compliance Trials Marketing 130

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. Mounjaro is the first weight loss drug to show efficacy rates comparable to surgical procedures like sleeve gastrectomies. Mounjaro is a combination of the two gut hormones GLP-1 and GIP.

Drugs 264

Drugs Manufacturing Hormones Contract Manufacturing 264

Pharmaceutical Technology

NOVEMBER 30, 2022

In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. Mounjaro is the first weight loss drug to show efficacy rates comparable to surgical procedures like sleeve gastrectomies. Mounjaro is a combination of the two gut hormones GLP-1 and GIP.

Drugs 246

Drugs Manufacturing Hormones Contract Manufacturing 246